Tofacitinib

small molecule

Identifier: CI-DRUG-00000596
Entity page: /drug/tofacitinib ↗
Edges: 50

Neighbours: 7 cancers4 genes10 trials22 approvals
Drawn: 43 of 43 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Tofacitinib approved for …APPROVED_FORderived22 of 22show fewer
→ approved for	FDA · US · 2026Efficacy supplement 2026-03-06 (see label) FDA (US) · approved · 2026-03-06 · Efficacy supplement 2026-03-06 (see label)	—	approved	not mapped	1	Regulatory	openfda	open ↗
→ approved for	FDA · US · 2026Efficacy supplement 2026-03-06 (see label) FDA (US) · approved · 2026-03-06 · Efficacy supplement 2026-03-06 (see label)

Tofacitinib targets …TARGETS4 of 4
→ targets	JAK2	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TYK2	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	JAK1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	JAK3	—	INHIBITOR	—	1	Curated	chembl	graph →

Tofacitinib targets …TARGETS4 of 4

→ targets

JAK2

—

INHIBITOR

—

Curated

Tofacitinib investigated in trials for …INVESTIGATED_IN_TRIALSderived7 of 7
→ investigated in trials for	Cholangiocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Epithelioid Mesothelioma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Epithelioid Mesothelioma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Extrahepatic Cholangiocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Extrahepatic Cholangiocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastomasubtype 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Nasal Type Extranodal NK/T-Cell Lymphoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nasal Type Extranodal NK/T-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Adenocarcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →

Tofacitinib studied in …STUDIED_INderived10 of 16show all (up to 200)
→ studied in	NCT06698822Phase 2 · recruiting A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA · 16 trials list this drug (2 active)	—	—	Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05326464Phase 3 · completed Tofacitinib in Recurrent GBM Patients · 16 trials list this drug (2 active)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04431895early Phase 1 · completed Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03976245Phase 4 · recruiting Advanced Therapeutics in Rheumatoid Arthritis (RA) · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04721821completed Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy. · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04034238Phase 1 · completed Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors · 16 trials list this drug (2 active)	—	—	Epithelioid Mesothelioma,Cholangiocarcinoma,Pancreatic Adenocarcinoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT04798287completed Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT02092467Phase 4 · completed Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01815424Phase 3 · completed A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT01186744Phase 3 · completed A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis · 16 trials list this drug (2 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths